1
|
Van den Brink M, Stiggelbout AM, van den
Hout WB, et al: Clinical nature and prognosis of locally recurrent
rectal cancer after total mesorectal excision with or without
preoperative radiotherapy. J Clin Oncol. 22:3958–3964.
2004.PubMed/NCBI
|
2
|
Collette L, Bosset JF, den Dulk M, et al:
Patients with curative resection of cT3-4 rectal cancer after
preoperative radiotherapy or radiochemotherapy: does anybody
benefit from adjuvant fluorouracil-based chemotherapy? A trial of
the European Organisation for Research and Treatment of Cancer
Radiation Oncology Group. J Clin Oncol. 25:4379–4386. 2007.
|
3
|
Rodel C, Martus P, Papadoupolos T, et al:
Prognostic significance of tumor regression after preoperative
chemoradiotherapy for rectal cancer. J Clin Oncol. 23:8688–8696.
2005. View Article : Google Scholar : PubMed/NCBI
|
4
|
Vironen J, Juhola M, Kairaluoma M, et al:
Tumour regression grading in the evaluation of tumour response
after different preoperative radiotherapy treatments for rectal
carcinoma. Int J Colorectal Dis. 20:440–445. 2005. View Article : Google Scholar
|
5
|
Vecchio FM, Valentini V, Minsky BD, et al:
The relationship of pathologic tumor regression grade (TRG) and
outcomes after preoperative therapy in rectal cancer. Int J Radiat
Oncol Biol Phys. 62:752–760. 2005. View Article : Google Scholar : PubMed/NCBI
|
6
|
Bujko K, Michalski W, Kepka L, et al:
Association between pathologic response in metastatic lymph nodes
after preoperative chemoradiotherapy and risk of distant metastases
in rectal cancer: an analysis of outcomes in a randomized trial.
Int J Radiat Oncol Biol Phys. 67:369–377. 2007. View Article : Google Scholar
|
7
|
Dhadda AS, Dickinson P, Zaitoun AM, et al:
Prognostic importance of Mandard tumour regression grade following
pre-operative chemo/radiotherapy for locally advanced rectal
cancer. Eur J Cancer. 47:1138–1145. 2011. View Article : Google Scholar
|
8
|
Topova L, Hellmich G, Puffer E, et al:
Prognostic value of tumor response to neoadjuvant therapy in rectal
carcinoma. Dis Colon Rectum. 54:401–411. 2011. View Article : Google Scholar : PubMed/NCBI
|
9
|
Jorgensen TJ: Enhancing radiosensitivity:
targeting the DNA repair pathways. Cancer Biol Ther. 8:665–670.
2009. View Article : Google Scholar : PubMed/NCBI
|
10
|
Maity A, McKenna WG and Muschel RJ: The
molecular basis for cell cycle delays following ionizing radiation:
a review. Radiother Oncol. 31:1–13. 1994. View Article : Google Scholar : PubMed/NCBI
|
11
|
Coleman CN: Hypoxia in tumors: a paradigm
for the approach to biochemical and physiologic heterogeneity. J
Natl Cancer Inst. 80:310–317. 1988. View Article : Google Scholar : PubMed/NCBI
|
12
|
Overgaard J: Hypoxic radiosensitization:
adored and ignored. J Clin Oncol. 25:4066–4074. 2007. View Article : Google Scholar : PubMed/NCBI
|
13
|
Deorukhkar A and Krishnan S: Targeting
inflammatory pathways for tumor radiosensitization. Biochem
Pharmacol. 80:1904–1914. 2010. View Article : Google Scholar : PubMed/NCBI
|
14
|
Baumann M, Krause M and Hill R: Exploring
the role of cancer stem cells in radioresistance. Nat Rev Cancer.
8:545–554. 2008. View
Article : Google Scholar : PubMed/NCBI
|
15
|
Zeki SS, Graham TA and Wright NA: Stem
cells and their implications for colorectal cancer. Nat Rev
Gastroenterol Hepatol. 8:90–100. 2011. View Article : Google Scholar : PubMed/NCBI
|
16
|
Yoshikawa R, Kusunoki M, Yanagi H, et al:
Dual antitumor effects of 5-fluorouracil on the cell cycle in
colorectal carcinoma cells: a novel target mechanism concept for
pharmacokinetic modulating chemotherapy. Cancer Res. 61:1029–1037.
2001.
|
17
|
Bateman AC, Jaynes E and Bateman AR:
Rectal cancer staging post neoadjuvant therapy - how should the
changes be assessed? Histopathology. 54:713–721. 2009. View Article : Google Scholar : PubMed/NCBI
|
18
|
Japanese Society for Cancer of the Colon
and Rectum. General rules for clinical and pathological studies on
cancer of the colon, rectum and anus. Kanehara & Co; Tokyo:
2006
|
19
|
Mandard AM, Dalibard F, Mandard JC, et al:
Pathologic assessment of tumor regression after preoperative
chemoradiotherapy of esophageal carcinoma. Clinicopathologic
correlations. Cancer. 73:2680–2686. 1994. View Article : Google Scholar
|
20
|
Dworak O, Keilholz L and Hoffmann A:
Pathological features of rectal cancer after preoperative
radiochemotherapy. Int J Colorectal Dis. 12:19–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
21
|
Saigusa S, Tanaka K, Toiyama Y, et al:
Correlation of CD133, OCT4, and SOX2 in rectal cancer and their
association with distant recurrence after chemoradiotherapy. Ann
Surg Oncol. 16:3488–3498. 2009. View Article : Google Scholar : PubMed/NCBI
|
22
|
Bijwaard KE, Aguilera NS, Monczak Y, et
al: Quantitative real-time reverse transcription-PCR assay for
cyclin D1 expression: utility in the diagnosis of mantle cell
lymphoma. Clin Chem. 47:195–201. 2001.PubMed/NCBI
|
23
|
Sauer R, Becker H, Hohenberger W, et al:
Preoperative versus postoperative chemoradiotherapy for rectal
cancer. N Engl J Med. 351:1731–1740. 2004. View Article : Google Scholar : PubMed/NCBI
|
24
|
Gerard JP, Chapet O, Nemoz C, et al:
Improved sphincter preservation in low rectal cancer with high-dose
preoperative radiotherapy: the lyon R96–02 randomized trial. J Clin
Oncol. 22:2404–2409. 2004.PubMed/NCBI
|
25
|
Guillem JG, Chessin DB, Cohen AM, et al:
Long-term oncologic outcome following preoperative combined
modality therapy and total mesorectal excision of locally advanced
rectal cancer. Ann Surg. 241:829–838. 2005. View Article : Google Scholar
|
26
|
Bosset JF, Collette L, Calais G, et al:
Chemotherapy with preoperative radiotherapy in rectal cancer. N
Engl J Med. 355:1114–1123. 2006. View Article : Google Scholar : PubMed/NCBI
|
27
|
Kaminsky-Forrett MC, Conroy T, Luporsi E,
et al: Prognostic implications of downstaging following
preoperative radiation therapy for operable T3-T4 rectal cancer.
Int J Radiat Oncol Biol Phys. 42:935–941. 1998. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chapet O, Romestaing P, Mornex F, et al:
Preoperative radiotherapy for rectal adenocarcinoma: which are
strong prognostic factors? Int J Radiat Oncol Biol Phys.
61:1371–1377. 2005. View Article : Google Scholar : PubMed/NCBI
|
29
|
Kim TH, Chang HJ, Kim DY, et al:
Pathologic nodal classification is the most discriminating
prognostic factor for disease-free survival in rectal cancer
patients treated with preoperative chemoradiotherapy and curative
resection. Int J Radiat Oncol Biol Phys. 77:1158–1165. 2010.
View Article : Google Scholar
|
30
|
Barker N, van Es JH, Kuipers J, et al:
Identification of stem cells in small intestine and colon by marker
gene Lgr5. Nature. 449:1003–1007. 2007. View Article : Google Scholar : PubMed/NCBI
|
31
|
Uchida H, Yamazaki K, Fukuma M, et al:
Overexpression of leucine-rich repeat-containing G protein-coupled
receptor 5 in colorectal cancer. Cancer Sci. 101:1731–1737. 2010.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Luo X, Huang Y and Sheikh MS: Cloning and
characterization of a novel gene PDRG that is differentially
regulated by p53 and ultraviolet radiation. Oncogene. 22:7247–7257.
2003. View Article : Google Scholar : PubMed/NCBI
|
33
|
Jiang L, Luo X, Shi J, et al: PDRG1, a
novel tumor marker for multiple malignancies that is selectively
regulated by genotoxic stress. Cancer Biol Ther. 11:567–573. 2011.
View Article : Google Scholar : PubMed/NCBI
|
34
|
Chung FY, Huang MY, Yeh CS, et al: GLUT1
gene is a potential hypoxic marker in colorectal cancer patients.
BMC Cancer. 9:2412009. View Article : Google Scholar : PubMed/NCBI
|
35
|
Brophy S, Sheehan KM, McNamara DA, et al:
GLUT-1 expression and response to chemoradiotherapy in rectal
cancer. Int J Cancer. 125:2778–2782. 2009. View Article : Google Scholar : PubMed/NCBI
|
36
|
Hofstadter F, Knuchel R and Ruschoff J:
Cell proliferation assessment in oncology. Virchows Arch.
427:323–341. 1995. View Article : Google Scholar
|
37
|
Herrmann JL, Byekova Y, Elmets CA, et al:
Liver kinase B1 (LKB1) in the pathogenesis of epithelial cancers.
Cancer Lett. 306:1–9. 2011. View Article : Google Scholar : PubMed/NCBI
|
38
|
Gurumurthy S, Xie SZ, Alagesan B, et al:
The Lkb1 metabolic sensor maintains haematopoietic stem cell
survival. Nature. 468:659–663. 2010. View Article : Google Scholar : PubMed/NCBI
|
39
|
Gan B, Hu J, Jiang S, et al: Lkb1
regulates quiescence and metabolic homeostasis of haematopoietic
stem cells. Nature. 468:701–704. 2010. View Article : Google Scholar : PubMed/NCBI
|
40
|
Yamaguchi H, Bhalla K and Wang HG: Bax
plays a pivotal role in thapsigargin-induced apoptosis of human
colon cancer HCT116 cells by controlling Smac/Diablo and Omi/HtrA2
release from mitochondria. Cancer Res. 63:1483–1489.
2003.PubMed/NCBI
|
41
|
Chang HJ, Jung KH, Kim DY, et al: Bax, a
predictive marker for therapeutic response to preoperative
chemoradiotherapy in patients with rectal carcinoma. Hum Pathol.
36:364–371. 2005. View Article : Google Scholar : PubMed/NCBI
|